关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
9 P8 w) |$ V2 X. e1 v7 \
% o0 O, t: Z, R) I( b& J2 L1 \6 t作者：来自澳大利亚
+ N$ A0 B4 H4 b% E7 p+ R: L来源：Haematologica. 2011.8.9.
( ]( S& b  G, vDear Group,
7 E8 j: J" E& Y; V
- \  f* ?6 w7 T# jSome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
; Q4 z5 N1 N4 {  w; i2 gtherapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
( Y- ?! r7 c8 k. }6 zdoes spike up the immune system so I hope more reports come out on this issue.
  n0 i& _0 \5 Y% |
The remarkable news about Sprycel cessation is that all 3 patients had failed
) B5 g  v5 e. W/ V6 HGleevec and Sprycel was their second TKI so they had resistant disease. This is
different from the stopping Gleevec trial in France which only targets patients
2 k+ N9 E2 d4 W) b( h! Rwho have done well on Gleevec.

Hopefully, the doctors will report on a larger study and long-term to see if the
: j/ M7 x9 s% r. o) jresponse off Sprycel is sustained.
) f4 J( H+ h" g; v0 E/ h
Best Wishes,
Anjana
& v! s5 d5 _) @& M


Haematologica. 2011 Aug 9. [Epub ahead of print]
. k- \) h  i  [' a6 }Durable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
! a2 K% ?0 s% C  R6 D* [Adelaide, Australia;
* U$ l+ f9 ]. Y
Abstract
Patients with chronic myeloid leukemia, treated with imatinib, who have a
; ]& t/ Q( b$ F1 r7 zdurable complete molecular response might remain in CMR after stopping
treatment. Previous reports of patients stopping treatment in complete molecular
response have included only patients with a good response to imatinib. We
describe three patients with stable complete molecular response on dasatinib
treatment following imatinib failure. Two of the three patients remain in
+ I# r* x' B! c/ v2 |complete molecular response more than 12 months after stopping dasatinib. In
4 Y2 q% I" _! v, F! Z; Sthese two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
show that the leukemic clone remains detectable, as we have previously shown in
; a' }* Y5 ~) F9 ]imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
who relapsed and in one patient in remission. Our results suggest that the
2 V# ~6 f: k: a7 Ncharacteristics of complete molecular response on dasatinib treatment may be
similar to that achieved with imatinib, at least in patients with adverse
disease features.
$ M/ y* w% g1 Z' l# B5 g! y9 ]) ^3 [

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
# H6 ]. r( G8 r  M  y( i- G    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
6 [9 M1 W! s$ w2 a3 ~2 d* k
作者：来自法国STIM试验
来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事